The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 348:1821-1822 May 1, 2003 Number 18
NextNext

Reversible Dementia Due to Thalidomide Therapy for Multiple Myeloma

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: Thalidomide is used to treat multiple myeloma because of its apoptotic1 and antiangiogenic2 properties. Common side effects of thalidomide in patients with multiple myeloma include sedation and peripheral neuropathy.3 We describe a case of reversible dementia due to thalidomide therapy for multiple myeloma.

A 66-year-old man with a history of coronary artery disease received a diagnosis of multiple myeloma in August 2001. In April 2002, he began a chemotherapy regimen of thalidomide (200 mg orally once a day) and dexamethasone (40 mg orally once a day on days 1 through 4, 9 through 12, and 17 through . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.